Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology by Maddalena, Alessia S. et al.
Neurodegenerative Dis 2004;1:231–235
DOI: 10.1159/000080991D i s e a s e s
Cerebrospinal Fluid Profile of Amyloid ß
Peptides in Patients with Alzheimer’s Disease
Determined by Protein Biochip Technology
Alessia S. Maddalenaa Andreas Papassotiropoulosa
Charo Gonzalez-Agostia Andri Signorella Thomas Hegib Thomas Paschb
Roger M. Nitscha Christoph Hocka
aDivision of Psychiatry Research and bInstitute of Anesthesiology, University of Zürich, Zürich, Switzerland
Christoph Hock, MD
Division of Psychiatry Research
Psychiatric University Hospital Zürich, Lenggstrasse 31
CH–8029 Zürich (Switzerland)
Tel. +41 44 384 2271, Fax +41 44 384 2275, E-Mail chock@bli.unizh.ch
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2004 S. Karger AG, Basel
1660–2854/04/0015–0231$21.00/0
Accessible online at:
www.karger.com/ndd
Key Words
Alzheimer’s disease W ß-Amyloid W Cerebrospinal fluid W
Protein biochip W ELISA
Abstract
Amyloid-ß peptides (Aß) are major components of amy-
loid plaques in the Alzheimer’s disease (AD) brain and
have been proposed as diagnostic markers in cerebro-
spinal fluid (CSF). Aß derived from brain may be pro-
cessed into fragments before emerging in CSF. There-
fore, we determined mass profiles of Aß peptides in CSF
of patients with AD and age-matched healthy control
subjects (CTR) by using protein biochip technology. Aß
peptides were captured on the chip surfaces (spots) by
the specific monoclonal antibody 6E10 and were then
analyzed by integrated surface-enhanced laser desorp-
tion and ionization time-of-flight mass spectrometry
(SELDI-TOF-MS). We found Aß species with mean mo-
lecular masses at 1,583.3 Da (corresponding to Aß2–14 ),
2,068.5 Da (Aß1–17), 2,166.4 Da (Aß1–18 ), 3,676.6 Da
(Aß1–33), 3,789.4 Da (Aß1–34), 4,076.9 Da (Aß1–37 ),
4,134.0 Da (Aß1–38), 4,233.3 Da (Aß1–39 ), 4,332.4 Da
(Aß1–40) and 4,516.8 Da (Aß1–42) in both AD (n = 24) and
CTR (n = 24) subjects. Aß1–38 appeared to be a major Aß
species in human CSF along with Aß1–40. Quantitation
revealed that CSF levels of Aß1–38 were significantly
decreased in AD as compared to CTR subjects. The CSF
profile of Aß peptides may be used for diagnostic and
therapeutic purposes in clinical studies.
Copyright © 2004 S. Karger AG, Basel
Introduction
ß-Amyloid (Aß) deposits, along with neurofibrillary
tangles, are the major histopathological hallmarks of Alz-
heimer’s disease (AD). The predominant protein compo-
nent of Aß plaques are strongly aggregating peptides with
an approximate molecular mass of 4 kDa [1–3]. Whereas
Aß42 is the major component of Aß plaques, Aß40 is most-
ly found in vascular amyloid of brain blood vessels [4].
Cerebrospinal fluid (CSF) levels of Aß42 measured by
ELISA were shown to be lower in AD patients as com-
pared to controls [for a review, see 5], while conflicting
results were reported from Aß40 measurements [6–12].
A number of reasons explaining the conflicting data
were discussed, including heterogeneity of the patient
sample and limitations of the ELISA method used, which
do not display the various fragments of peptides captured
by the monoclonal antibodies.
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Fig. 1. Potential cleavage sites of Aß peptide: secretases and putative proteases. · = Alpha secretase; ß = beta secretase
(BACE 1 and 2); Á = gamma secretase; DPP = dipeptidyl peptidase; IDE = insulin-degrading enzyme; ECE = endothelin-
converting enzyme 1 (ECE-1); NEP = neprilysin; COL = collagenase; MMP = matrix metalloproteinase 9 (MMP-9);
CAD = cathepsin D; PDD = peptidyl dipeptidase.
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To clarify the patterns of Aß peptides present in CSF
we determined mass profiles of Aß in patients with AD, as
well as in age-matched healthy control subjects (CTR) by
using a protein biochip technology (SELDI, Ciphergen)
[13–17].
Subjects and Methods
Subjects
A diagnosis of probable AD was made according to NINCDS-
ADRDA criteria [18] as well as ICD10 [19]. The clinical workup
included neuropsychological testing, MRI scans and routine CSF
investigations. The mean Mini-Mental State Examination (MMSE)
scores were 21 B 5.8 (SD) in the AD group (n = 24). The mean age
(SD) was 71.2 B 9 years; there were 10 females and 14 males.
Healthy CTR (n = 24) were recruited among cognitively intact
patients undergoing spinal anesthesia before surgical intervention.
The mean age was 65.7 B 12 years; there were 8 females and 16
males. The study was approved by the local ethics committee and
subjects gave written informed consent prior to the investigation.
CSF was obtained by lumbar puncture, aliquoted, immediately fro-
zen at the bedside (–80 °C) and freshly thawed prior to the analyses.
Protein Biochip Analysis
Capturing Aß peptides from CSF was done on SELDI Protein
G-coated (PG20) ProteinChip® Arrays (Ciphergen Biosystems, Palo
Alto, Calif., USA). Like PS20 ProteinChips, PG20 ProteinChip
Arrays contain an epoxy surface which covalently reacts with amine
and thiol groups and allows precoupling with recombinant Protein
G. The specific monoclonal antibody 6E10 against Aß epitope 1–17
(Signet Pathology Systems, Dedham, Mass., USA) was first purified
on Protein G columns [ImmunoPure Protein (G) IgG Purification
Kit, Pierce Biotechnology, Rockford, Ill., USA] and then added (2 Ìl
of 0.2 mg/ml) on the microspots followed by incubation in a humidi-
ty chamber at room temperature for 1 h. Antibody solution was
removed and the chip array was washed once in bulk with 8 ml phos-
phate buffer saline (PBS, pH 7.4) containing 0.5% (v/v) Triton X-100
for 10 min, then twice in bulk with 8 ml PBS for 5 min. The spots
were coated with 5 Ìl crude CSF and incubated in a humidity cham-
ber at 4°C overnight. CSF was removed and spots were washed; first
in bulk with 8 ml PBS (pH 7.4) containing 0.5% (v/v) Triton X-100
for 10 min, then washed in bulk twice with 8 ml PBS for 5 min, and
finally rinsed with 1 mM HEPES buffer. ·-Cyano-4-hydroxy cin-
namic acid (CHCA) was dissolved in 50% (v/v) acetonitrile, 0.1%
(v/v) trifluoroacetic acid. After drying, a 1:5 diluted solution of
CHCA was added to the spots (0.5 Ìl) and mass identification was
made by 100 averaged shots in a Ciphergen SELDI Protein Biology
System II (PBS II). All data were normalized against a common
matrix peak. Signal to noise (S/N) ratios above 2.5 were considered to
be sufficient to submit the data to statistical analysis.
Statistical Analysis
Group comparisons were done by nonparametric Mann-Whitney
U tests. Statistical significance was assumed at p ! 0.05.
Results
We found CSF species of Aß peptides with mean
molecular masses at 1,583.3 Da (corresponding to
Aß2–14), 2,068.5 Da (Aß1–17), 2,166.4 Da (Aß1–18),
3,676.6 Da (Aß1–33), 3,789.4 Da (Aß1–34), 4,076.9 Da
(Aß1–37), 4,134.0 Da (Aß1–38), 4,233.3 Da (Aß1–39),
4,332.4 Da (Aß1–40) and 4,516.8 Da (Aß1–42) in both AD
(n = 24) and CTR (n = 24) subjects (fig. 1a). Mass detec-
tion showed high accuracy with minimal intersample
deviation and corresponded well to calculated peptide
masses (table 1, fig. 1).
Aß1–38 and Aß1–40 were the most prominent Aß species
in CSF and fulfilled the requirement of an S/N ratio over
2.5 for quantitation (fig. 2a, b).
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Fig. 2. a CSF profile of Aß peptides (1 subject) captured by monoclonal antibody 6E10 on a protein biochip.
b Percentage of Aß peptide peaks with an S/N ratio higher than 2.5.
Table 1. CSF Aß peptides captured by monoclonal 6E10 antibody
Aß
peptides
Mean MW
observed, Da
SD
Da
MW calculated
Da
Amino acid sequence
2–14 1,583.3 0.08 1,583.6 AEFRHDSGYEVHH
17 2,068.5 0.69 2,068.2 DAEFRHDSGYEVHHQKL
18 2,166.4 0.65 2,167.3 DAEFRHDSGYEVHHQKLV
33 3,676.6 0.89 3,674.0 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG
34 3,789.4 0.85 3,787.2 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL
37 4,076.9 0.98 4,074.5 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVG
38 4,134.0 1.00 4,131.6 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG
39 4,233.3 1.10 4,230.7 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
40 4,332.4 1.00 4,329.9 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
42 4,516.8 1.63 4,514.1 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Mean MW with standard deviation (SD) in daltons, calculated peptide MW in daltons and amino acid sequence. Only peaks with an S/N
ratio higher than 2.5 were included in the analyses.
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Fig. 3. CSF Aß1–38 (a) and Aß1–40 (b) peak intensity measured on the protein biochip after normalization to a
common matrix peak in patients with AD and CTR. * p = 0.001 (a) and * p = 0.000 (b), Mann-Whitney test. Only
peaks with an S/N ratio higher than 2.5 were included in calculations. c Mean peak intensity Aß1–38/Aß1–40 ratio in
CSF of patients with AD and CTR. * p ! 0.01, Mann-Whitney U test.
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The mean peak intensity corresponding to Aß1–38
[mean molecular weight (MW) 4,134 Da] was lower in
CSF of AD patients (mean 8.65 B 1.12 SE, n = 23), as
compared to CTR (22.28 B 4.25, n = 24; p ! 0.01, Mann-
Whitney U test) (fig. 3a). Similarly, the mean peak inten-
sity corresponding to Aß1–40 (mean MW 4,332.4 Da) was
lower in CSF of AD patients (mean 7.55 B 1.18 SE, n =
21) as compared to CTR (23.98 B 4.25, n = 24; p ! 0.01,
Mann-Whitney U test) (fig. 3b).
The mean peak intensity of the Aß1–38/Aß1–40 ratio was
significantly higher in CSF of the AD patients (1.43 B
0.15 SE, n = 21), as compared to CTR (0.95 B 0.08, n =
24; p = 0.01, Mann-Whitney U test) (fig. 3c).
Discussion
We have determined mass profiles of Aß peptides in
human CSF by using protein biochip technology. We
found Aß species corresponding to Aß1–40 and Aß1–42
(4,333.5 and 4,517.7 Da, respectively), and additionally
detected Aß species corresponding to Aß2–14, Aß1–17,
Aß1–18, Aß1–33, Aß1–34, Aß1–37, Aß1–38 and Aß1–39 in
both AD patients and CTR subjects. Presence of Aß
species with similar mass profiles was recently reported
in cell culture media, measured by immunoprecipita-
tion-MALDI-TOF mass-spectrometric analysis (IP/MS)
[20, 21], immunoprecipitation-HPLC-mass spectrometry
[22], as well as by SELDI technology [13–16]. In human
CSF, several of the mass peaks found in the present analy-
ses, including Aß1–38, were also identified by MALDI-
TOF [6] and SELDI [17]. Thus, protein biochip technolo-
gy may allow for detection of a heterogeneous population
of truncated Aß peptides in human CSF. The exact origin
of the various Aß species is currently not known; in addi-
tion to the action of the APP secretases and endopepti-
dases, such as IDE and neprelysin (see fig. 1), other yet
unidentified proteases may be involved. Interestingly
Aß1–38 turned out to be one of the most prominent Aß
peptide in CSF, particularly in AD patients, where it
showed an even higher peak intensity than Aß1–40. These
results are in line with a recent report of increased Aß1–38
(in percent, relative to total Aß) in CSF of patients with
AD, as well as chronic neuroinflammation [6].
The generation of Aß1–38 peptide is still a matter of dis-
cussion. Beher et al. [16] showed that such C-terminally
truncated peptides are generated by action of Á-secretase
and not by a separate enzyme entity. In a cell culture mod-
el, Weggen et al. [23] and De Strooper and Konig [24] also
demonstrated an increase of Aß1–38 peptides and a de-
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crease of Aß1–42 upon administration of nonsteroidal anti-
inflammatory drugs with potential Á-secretase activities.
In conclusion, protein biochip technology may allow
for both mass profiling and relative quantitation of Aß
species in human CSF, and may thus expand the method-
ological repertoire of diagnostic and therapeutic biomark-
er research in AD.
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